Help Get Patients to Their LDL-C and A1C Goals: Welchol® (colesevelam HCl) and the ADDvantage Program™

Published Online: Friday, June 1, 2012
This product bulletin was brought to you by Daiichi Sankyo, Inc.

This product bulletin describes the efficacy and safety of Welchol, a bile acid sequestrant. Welchol is the first and only add-on to a statin and metformin that is approved by the FDA as an adjunct to diet and exercise to lower both low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (A1C) levels in adults with primary hyperlipidemia and type 2 diabetes mellitus. It also describes the ADDvantage Program, an innovative program to help keep patients on their LDL-C and A1C medications by enabling them to save money on multiple prescriptions and providing valuable resources and tools to help get them to their LDL-C and A1C goals.

To view the  Welchol® (colesevelam HCl) product information, please click here

To view the full product bulletin, please click here or the image below.



Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$